GM-CSF inhibition reduces cytokine release syndrome and neuroinflammation but enhances CAR-T cell function in xenografts

Rosalie M. Sterner; Reona Sakemura; Michelle J. Cox; Nan Yang; Roman H. Khadka; Cynthia L. Forsman; Michael J. Hansen; Fang Jin; Katayoun Ayasoufi; Mehrdad Hefazi; Kendall J. Schick; Denise K. Walters; Omar Abdihamid; Dale Chappell; Tarek Sahmoud; Cameron Durrant; Wendy K. Nevala; Mrinal M. Patnaik; Larry R. Pease; Karen E. Hedin; Neil E. Kay; Aaron J. Johnson; Saad S. Kenderian

doi:10.1182/blood-2018-10-881722

Ask about this paper

Answers are grounded in this paper and cite their sources.

Abstract

CAR-T cells maintained normal functions and had enhanced antitumor activity in vivo, as well as improved overall survival, compared with CART19 cells. Together, these studies illuminate a novel approach to abrogate NI and CRS through GM-CSF neutralization, which may potentially enhance CAR-T cell function. Phase 2 studies with lenzilumab in combination with CART19 cell therapy are planned.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Sterner et al. (2018) studied this question.

synapsesocial.com/papers/6a0042c1f9353b931b7746f1 https://doi.org/10.1182/blood-2018-10-881722

View Full Paper

Ask AI

Bookmark

Share

GM-CSF inhibition reduces cytokine release syndrome and neuroinflammation but enhances CAR-T cell function in xenografts

Ask about this paper

Abstract

Discussion

Cite This Study

GM-CSF inhibition reduces cytokine release syndrome and neuroinflammation but enhances CAR-T cell function in xenografts

Ask about this paper

Abstract

Discussion

Cite This Study

Keep reading

Keep reading